Windtree Therapeutics Inc... (WINT)
0.14
-0.02 (-11.56%)
At close: Jan 28, 2025, 2:35 PM
undefined% (undefined)
| Bid | 0.14 |
| Market Cap | 1.58M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -22.01 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.14 |
| Volume | 3,028,214 |
| Avg. Volume (20D) | 3,025,486 |
| Open | 0.15 |
| Previous Close | 0.16 |
| Day's Range | 0.14 - 0.16 |
| 52-Week Range | 0.14 - 14.75 |
| Beta | undefined |
About WINT
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF,...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 7, 1995
Employees 20
Stock Exchange NASDAQ
Ticker Symbol WINT
Website https://windtreetx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for WINT stock is "Hold." The 12-month stock price forecast is $7, which is an increase of 4781.45% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
3 months ago
+43.27%
Windtree Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
4 months ago
+4.08%
Windtree Therapeutics shares are trading higher after the company completed enrollment of its Phase 2b study of Istaroxime in early cardiogenic shock caused by heart failure.
